Gilead Sciences stock: Bank of America raises target for Gilead Sciences stock to USD 172

Published on 10/21/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 7.80 billion. Gilead Sciences stock costs EUR 137.08 on October 21, 2026, down 1.57 percent versus the Xetra close.

Bank of America target raised to USD 172

Bank of America lifted its Gilead Sciences target to USD 172 on October 20, 2026.
Second-quarter revenue reached USD 7.80 billion versus USD 7.40 billion consensus.
Gilead Sciences stock costs EUR 137.08 at Lang & Schwarz on October 21, 2026 at 5:01 p.m. CEST, 1.57 percent below the Xetra close.
Gilead Sciences is scheduled to report results on October 29, 2026.

Schwarzweiß-Reportage: Gilead Sciences Forscherin am Mikroskop im Biopharma-Labor — Gilead Sciences ISIN US3755581036 Schwarzweiß-Reportage Forscherin untersucht Zellkulturen am Mikroskop im Labor, Illustration mit AI erstellt.

Bank of America raised its Gilead Sciences price target from USD 168.00 to USD 172.00 and maintained a Buy rating in a note dated October 20, 2026, according to MarketBeat. Gilead Sciences was trading at EUR 137.08 at Lang & Schwarz on October 21, 2026 at 5:01 p.m. CEST, down 1.57 percent versus the Xetra close of October 20, 2026 at EUR 139.26.

Revenue beats consensus

For the second quarter of 2026, Gilead Sciences reported revenue of USD 7.80 billion against USD 7.40 billion consensus, a 5.41 percent difference. MarketBeat said the quarter's revenue was 10.60 percent above the year-earlier level, while the company posted a reported loss per share.

Stock sits below its yearly high

The US-listed stock was at USD 153.84 on the Nasdaq on October 21, 2026 at 11:04 a.m. ET. That level was 4.16 percent below the 52-week high of USD 160.51 and 34.92 percent above the 52-week low of USD 114.02. Trading volume stood at 2,034,875 shares at that timestamp.

Earnings date and valuation

Gilead Sciences is expected to report its next results after the close on October 29, 2026, according to Gekko. The same page lists a consensus revenue estimate of USD 7.79 billion and earnings per share of USD 2.18 for that report. The current market capitalization is USD 190.8 billion, and the trailing price-to-earnings ratio is minus 57.62.

Comparison with peers

Gilead Sciences: down 1.57 percent versus the Xetra close, price-to-earnings ratio minus 57.62, market capitalization USD 190.8 billion.

Amgen (Nasdaq, USD): down 0.35 percent on October 21, 2026, price-to-earnings ratio 27.19, market capitalization USD 236.5 billion.

Vertex Pharmaceuticals (Nasdaq, USD): up 0.41 percent on October 21, 2026, price-to-earnings ratio 30.10, market capitalization USD 131.0 billion.

Target leaves room above the price

Bank of America's USD 172.00 target stood 11.81 percent above the USD 153.84 Nasdaq price on October 21, 2026. The contrast between that target and the negative trailing earnings ratio puts the coming quarterly report at the center of the valuation discussion.

The euro quotation stayed below the October 20 Xetra close during the regular Xetra session on October 21, 2026. Gilead Sciences was trading at EUR 137.08 at Lang & Schwarz on October 21, 2026 at 5:01 p.m. CEST, 1.57 percent below the Xetra close of October 20, 2026 at EUR 139.26. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.